½É¹æ¼¼µ¿ Ä¡·á ½ÃÀå º¸°í¼­ : Áúȯ À¯Çüº°, Ä¡·á À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°(2025-2033³â)
Atrial Fibrillation Treatment Market Report by Disorder Type, Treatment Type, End-User, and Region 2025-2033
»óǰÄÚµå : 1800932
¸®¼­Ä¡»ç : IMARC
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 117 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,999 £Ü 4,196,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ® µîÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 3,999 £Ü 5,596,000
PDF & Excel (5 User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ Copy&Paste°¡ ºÒ°¡´ÉÇÕ´Ï´Ù. Àμâ´Â 5ºÎ±îÁö °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,999 £Ü 6,995,000
PDF & Excel (Corporate License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ Copy&Paste°¡ ºÒ°¡´ÉÇÕ´Ï´Ù. Àμâ´Â 5ºÎ±îÁö °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ½É¹æ¼¼µ¿ Ä¡·á ½ÃÀå ±Ô¸ð´Â 2024³â 86¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC GroupÀº 2033³â±îÁö 209¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â ¿¬Æò±Õ ¼ºÀå·ü(CAGR)Àº 9.83%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.

½É¹æ¼¼µ¿(AFib)Àº ºÒ±ÔÄ¢ÇÏ°í ºü¸¥ ½ÉÀå ¹Úµ¿À¸·Î ³úÁ¹Áß, ½ÉºÎÀü ¹× ±âŸ ½ÉÀå °ü·Ã ÇÕº´ÁõÀÇ À§ÇèÀ» Áõ°¡½ÃŰ´Â ½ÉÀå ÁúȯÀÔ´Ï´Ù. ÀÌ »óÅ¿¡¼­´Â ½É¹æ»ó½ÇÀÌ ºÒ±ÔÄ¢ÇÏ°Ô ¹Úµ¿ÇÏ°í ½É½ÇÇϽǰú ¿¬µ¿ÇÏÁö ¾Ê¾Æ ½É°èÇ×Áø, È£Èí°ï¶õ, ÇǷΰ¨À» À¯¹ßÇÕ´Ï´Ù. ¶ÇÇÑ Ç÷Àü ¹ß»ýÀ¸·Î À̾îÁ® ´Ù¸¥ Àå±â·ÎÀÇ Ç÷·ù¸¦ ¹æÇØÇÒ ¼öµµ ÀÖ½À´Ï´Ù. ½É¹æ¼¼µ¿ÀÇ ÁÖ¿ä À¯Çü¿¡´Â ¹ßÀÛ¼º ½É¹æ¼¼µ¿, Áö¼Ó¼º ½É¹æ¼¼µ¿, Àå±â Áö¼Ó¼º ½É¹æ¼¼µ¿, Áö¼Ó¼º ½É¹æ¼¼µ¿ÀÌ ÀÖÀ¸¸ç, ½ÉÀåÀÇ Àü±â ÀÚ±ØÀ» Á¶ÀýÇÏ´Â ¾à¹° ¹× ±âŸ °³ÀÔÀ» ÅëÇØ Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÉÇ÷°ü Áúȯ(CVDs)ÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀº ³ëÀÎ Àα¸¿Í ´ç´¢º´, °íÇ÷¾Ð, ½ÉÇ÷°ü Áúȯ(CVDs)°ú °°Àº ´Ù¸¥ ÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷µé »çÀÌ¿¡¼­ ¸Å¿ì ÈçÇÏ°Ô ³ªÅ¸³³´Ï´Ù. ÀÌ´Â Àü ¼¼°èÀûÀ¸·Î ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ´Â ³ëÀÎ Àα¸¿Í ÇÔ²² ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÃÖ¼Òħ½À(MI) ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ ¼ÒÇüÈ­ ¼ö¼ú Àåºñ, ÀÓÇöõÆ® ¼ö¼ú, ¿ø°Ý °£È£¿¡ ´ëÇÑ ¼ö¿ä¿¡µµ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼Õ»óµÈ ½ÉÀå Á¶Á÷À» Á¦°ÅÇϱâ À§ÇÑ Ä«Å×ÅÍ ÀýÁ¦ ÀåÄ¡¿Í Çõ½ÅÀûÀÎ ¸ÅÇÎ ¹× ±â·Ï ½Ã½ºÅÛ °³¹ß µî ´Ù¾çÇÑ ±â¼ú ¹ßÀüµµ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ±âŸ ¿äÀÎÀ¸·Î´Â ÀÇ·á ÀÎÇÁ¶óÀÇ °³¼±°ú ÀÇ·á °úÇÐ ºÐ¾ßÀÇ ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß(R&D) Ȱµ¿ÀÌ ½ÃÀåÀ» ´õ¿í °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

Á¦5Àå ¼¼°èÀÇ ½É¹æ¼¼µ¿ Ä¡·á ½ÃÀå

Á¦6Àå ½ÃÀå ºÐ¼® : Áúȯ À¯Çüº°

Á¦7Àå ½ÃÀå ºÐ¼® : Ä¡·á À¯Çüº°

Á¦8Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

Á¦9Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

Á¦10Àå SWOT ºÐ¼®

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå PorterÀÇ Five Forces ºÐ¼®

Á¦13Àå °æÀï ±¸µµ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global atrial fibrillation treatment market size reached USD 8.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 20.9 Billion by 2033, exhibiting a growth rate (CAGR) of 9.83% during 2025-2033.

Atrial fibrillation (AFib) refers to a cardiac condition with irregular and rapid heart rate that increases the risks of stroke, heart failure and other heart-related complications. In this condition, the upper (atrial) chambers beat irregularly and out of coordination with the lower (ventricle) chambers of the heart, thereby causing heart palpitations, shortness of breath and fatigue. It can also lead to the development of blood clots that may disrupt the blood flow to other organs. The main types of AFib include paroxysmal, persistent, long-term persistent, and permanent AFib that can be treated with medications and other interventions to adjust the heart's electrical impulses.

The rising prevalence of cardiovascular diseases (CVDs) is one of the key factors driving the growth of the market. Such disorders are highly prevalent among the geriatric population and individuals suffering from other ailments, such as diabetes, hypertension and cardiovascular diseases (CVDs). This, along with the steadily increasing geriatric population across the globe, is providing a boost to the market growth. Furthermore, the increasing preference for minimally invasive (MI) surgical procedures is also creating a positive impact on the demand for miniaturized surgical devices, implant surgeries and remote nursing. Additionally, various technological advancements, such as the development of catheter ablation devices to remove damaged heart tissues and innovative mapping and recording systems, is acting as another growth-inducing factor. Other factors, including improvements in the healthcare infrastructure and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.

Key Market Segmentation:

Breakup by Disorder Type:

Breakup by Treatment Type:

Breakup by End-User:

Breakup by Region:

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Atricure Inc., Biotronik, Boston Scientific Corporation, Cardiofocus Inc., Hansen Medical Inc. (Auris Health), Johnson & Johnson, Siemens Healthineers, Stereotaxis Inc., etc.

Key Questions Answered in This Report:

Table of Contents

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Atrial Fibrillation Treatment Market

6 Market Breakup by Disorder Type

7 Market Breakup by Treatment Type

8 Market Breakup by End-User

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â